Results From Ongoing Phase 2 Trial of SL-401 as Consolidation Therapy in Patients With Acute Myeloid Leukemia (AML) in Remission With High Relapse Risk Including Minimal Residual Disease (MRD)
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in…
Results From Ongoing Phase 2 Trial of SL-401 in Patients With Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. ASH 2016
Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced,…
Results From Ongoing Phase 1/2 Trial of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide…
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1)
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and…
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess…
SL-401, a Novel IL-3R/CD123-Directed Agent Targets Stem-Like Cells in Multiple Myeloma
SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-Like Cells in Multiple…
Results From Ongoing Phase 2 Registration Study of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Results From Ongoing Phase 2 Registration Study Of SL-401 In Patients With…
Results From Phase 2 Registration Trial of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing
Results From Phase 2 Registration Trial of SL-401 in Patients with Blastic…
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor…
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts…